Opdivo 40 or 100 mg

Opdivo Opdivo 40mg

Opdivo Opdivo 100mg

Nivolumab (Nivolumab) produced by the company Bristol-Myers Squibb under the commercial name "Opdivo" (Opdivo), was approved by the FDA in late 2014 for use in advanced stages of melanoma and in 2015 received approval for the treatment of non-small cell lung cancer. Opdivo (Nivolumab) refers to drugs aimed (targeted) action and is applied in the therapy of the most aggressive malignancies. The drug inhibits the growth of tumor and prevents the development of metastases. Already used in Israel.Pharmacological groupon refers to a group of new pharmacological blockers of the receptor PD-1.

Indications.

The drug nivolumab used in:patients with progressive unresectable melanoma;in the presence of melanoma, which is accompanied by a mutation of the gene BRAF, if the use of BRAF inhibitors does not bring the expected effect;in patients with progressive metastatic squamous cell lung cancer.Method primenenyat only under the supervision of a specialist oncologist, drip intravenously over 60 minutes every two weeks. To determine the dosage and frequency of admission can only be a doctor who conducts a patient's entire period of therapy. It is based on the results of control tests is able to adjust the course.

Side effects.

In General, the drug has a good tolerability. But when using it side effects, of course, possible. Most common skin rash in approximately every fifth patient. Other side effects are more rare.

There are various dosage - the drug is available in the form of a solution 40 mg/4 ml (40 Opdivo) and 100 mg/10 ml (100 Opdivo).

Delivery in Ukraine New Mail.

Payment upon receipt or

to PrivatBank card.

Delivery is possible in Russia, Moldova and Belarus.

Bring to order any medication from countries

Of the European Union, India, Turkey, Russia and Belarus.

Tel: 0675621331 (Viber); 0999875213 —

call, write — order!

Check out our features!